Heritage Trust Co Has $10.65 Million Position in Johnson & Johnson (NYSE:JNJ)

Heritage Trust Co cut its position in Johnson & Johnson (NYSE:JNJFree Report) by 1.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,373 shares of the company’s stock after selling 1,249 shares during the quarter. Johnson & Johnson comprises 1.7% of Heritage Trust Co’s investment portfolio, making the stock its 7th biggest position. Heritage Trust Co’s holdings in Johnson & Johnson were worth $10,649,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Hibernia Wealth Partners LLC bought a new stake in Johnson & Johnson during the third quarter valued at approximately $27,000. FNY Investment Advisers LLC purchased a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $37,000. Tower View Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 165 shares during the last quarter. Creative Capital Management Investments LLC grew its position in Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after acquiring an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC bought a new position in Johnson & Johnson in the second quarter valued at $48,000. 68.40% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 0.7 %

NYSE JNJ opened at $157.87 on Tuesday. The stock has a market cap of $380.04 billion, a P/E ratio of 11.43, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The stock has a 50 day simple moving average of $158.18 and a two-hundred day simple moving average of $158.62. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company’s revenue for the quarter was down 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.35 EPS. On average, analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th will be given a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date of this dividend is Friday, February 16th. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on JNJ shares. Morgan Stanley cut their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Raymond James increased their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, January 24th. Finally, UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the company from $167.00 to $180.00 in a research report on Friday, December 1st. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $176.14.

View Our Latest Report on Johnson & Johnson

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.